Clinical Trial Update: Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Utidelone to Docetaxel in HER2-negative locally advanced or metastatic breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Utidelone (utidelone)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer | Phase 3 | Status: RECRUITING